Clinical Trials Browser

Recruiting × INDUSTRY × dostarlimab × Clear all

NCT06567782 2026-03-12

AZUR-4

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT06405230 2026-02-03

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05855200 2026-01-23

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Phase 3 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT07108270 2025-12-22

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

Phase 2 Recruiting

Endometrial Neoplasms

NCT05277051 2025-12-19

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06796907 2025-10-14

BEHOLD-2

Phase 1/2 Recruiting

Neoplasms

NCT06256588 2025-09-25

JADE

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms